AxoGen, Inc. (NASDAQ:AXGN) Receives Consensus Rating of “Moderate Buy” from Brokerages

AxoGen, Inc. (NASDAQ:AXGN) has earned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $51.5556.

AXGN has been the topic of a number of recent analyst reports. Citigroup reiterated a “market outperform” rating on shares of AxoGen in a research report on Thursday, July 30th. Wall Street Zen upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a report on Sunday, July 26th. Truist Financial started coverage on shares of AxoGen in a research report on Wednesday, August 26th. They set a “buy” rating and a $60.00 price objective on the stock. Citizens Jmp upped their price objective on shares of AxoGen from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Thursday, July 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AxoGen in a research report on Wednesday, August 26th.

Insider Transactions at AxoGen

In other AxoGen news, Director Amy Wendell sold 13,353 shares of AxoGen stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $48.42, for a total value of $646,552.26. Following the completion of the transaction, the director directly owned 107,976 shares of the company’s stock, valued at approximately $5,228,197.92. The trade was a 11.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Joseph A. Tyndall sold 3,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total transaction of $173,950.00. Following the completion of the transaction, the director owned 10,650 shares of the company’s stock, valued at approximately $529,305. The trade was a 24.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,503 shares of company stock worth $4,656,947 in the last ninety days. 2.44% of the stock is owned by company insiders.

Institutional Investors Weigh In On AxoGen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Lisanti Capital Growth LLC purchased a new position in shares of AxoGen in the 2nd quarter worth $4,183,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of AxoGen during the 2nd quarter valued at about $1,469,000. Legato Capital Management LLC purchased a new stake in shares of AxoGen during the 4th quarter valued at about $1,323,000. TimesSquare Capital Management LLC bought a new position in shares of AxoGen in the 2nd quarter valued at about $31,863,000. Finally, Rice Hall James & Associates LLC bought a new position in shares of AxoGen in the 2nd quarter valued at about $3,414,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Price Performance

Shares of AXGN traded down $0.15 during trading hours on Friday, reaching $45.13. 65,281 shares of the company’s stock traded hands, compared to its average volume of 1,108,969. AxoGen has a 12 month low of $15.27 and a 12 month high of $52.91. The stock has a market cap of $2.43 billion, a PE ratio of -66.39 and a beta of 1.16. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07. The firm’s 50 day simple moving average is $45.25 and its 200-day simple moving average is $40.82.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 EPS for the quarter, hitting analysts’ consensus estimates of $0.12. The business had revenue of $69.73 million during the quarter, compared to analysts’ expectations of $67.10 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. Equities analysts expect that AxoGen will post -0.45 EPS for the current year.

About AxoGen

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on the repair and regeneration of damaged peripheral nerves. The company develops and markets biologic and surgical products intended to help restore sensory and motor function following traumatic nerve injuries or surgical procedures.

Its product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves; Axoguard Nerve Connector, designed to protect and support the repair of smaller nerve injuries; and Axoguard Nerve Protector, a collagen-based product intended to help protect repaired nerves and reduce the effects of scar tissue.